417 related articles for article (PubMed ID: 29306194)
1. Downregulation of PARP1 transcription by CDK4/6 inhibitors sensitizes human lung cancer cells to anticancer drug-induced death by impairing OGG1-dependent base excision repair.
Tempka D; Tokarz P; Chmielewska K; Kluska M; Pietrzak J; Rygielska Ż; Virág L; Robaszkiewicz A
Redox Biol; 2018 May; 15():316-326. PubMed ID: 29306194
[TBL] [Abstract][Full Text] [Related]
2. Targeting OGG1 arrests cancer cell proliferation by inducing replication stress.
Visnes T; Benítez-Buelga C; Cázares-Körner A; Sanjiv K; Hanna BMF; Mortusewicz O; Rajagopal V; Albers JJ; Hagey DW; Bekkhus T; Eshtad S; Baquero JM; Masuyer G; Wallner O; Müller S; Pham T; Göktürk C; Rasti A; Suman S; Torres-Ruiz R; Sarno A; Wiita E; Homan EJ; Karsten S; Marimuthu K; Michel M; Koolmeister T; Scobie M; Loseva O; Almlöf I; Unterlass JE; Pettke A; Boström J; Pandey M; Gad H; Herr P; Jemth AS; El Andaloussi S; Kalderén C; Rodriguez-Perales S; Benítez J; Krokan HE; Altun M; Stenmark P; Berglund UW; Helleday T
Nucleic Acids Res; 2020 Dec; 48(21):12234-12251. PubMed ID: 33211885
[TBL] [Abstract][Full Text] [Related]
3. OGG1-initiated base excision repair exacerbates oxidative stress-induced parthanatos.
Wang R; Li C; Qiao P; Xue Y; Zheng X; Chen H; Zeng X; Liu W; Boldogh I; Ba X
Cell Death Dis; 2018 May; 9(6):628. PubMed ID: 29795387
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's disease-associated polymorphisms in human OGG1 alter catalytic activity and sensitize cells to DNA damage.
Jacob KD; Noren Hooten N; Tadokoro T; Lohani A; Barnes J; Evans MK
Free Radic Biol Med; 2013 Oct; 63():115-25. PubMed ID: 23684897
[TBL] [Abstract][Full Text] [Related]
5. Oxidative DNA damage and reduced expression of DNA repair genes: Role in primary open angle glaucoma (POAG).
Mohanty K; Dada R; Dada T
Ophthalmic Genet; 2017; 38(5):446-450. PubMed ID: 28129013
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose) polymerase 1 (PARP-1) binds to 8-oxoguanine-DNA glycosylase (OGG1).
Noren Hooten N; Kompaniez K; Barnes J; Lohani A; Evans MK
J Biol Chem; 2011 Dec; 286(52):44679-90. PubMed ID: 22057269
[TBL] [Abstract][Full Text] [Related]
7. Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity.
Jin D; Tran N; Thomas N; Tran DD
PLoS One; 2019; 14(10):e0223555. PubMed ID: 31600301
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
9. CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms.
Skowron MA; Vermeulen M; Winkelhausen A; Becker TK; Bremmer F; Petzsch P; Schönberger S; Calaminus G; Köhrer K; Albers P; Nettersheim D
Br J Cancer; 2020 Aug; 123(3):378-391. PubMed ID: 32418994
[TBL] [Abstract][Full Text] [Related]
10. PARP1 promoter links cell cycle progression with adaptation to oxidative environment.
Pietrzak J; Spickett CM; Płoszaj T; Virág L; Robaszkiewicz A
Redox Biol; 2018 Sep; 18():1-5. PubMed ID: 29886395
[TBL] [Abstract][Full Text] [Related]
11. Ribociclib mitigates cisplatin-associated kidney injury through retinoblastoma-1 dependent mechanisms.
Kim JY; Jayne LA; Bai Y; Feng MJHH; Clark MA; Chung S; W Christman J; Cianciolo RE; Pabla NS
Biochem Pharmacol; 2020 Jul; 177():113939. PubMed ID: 32229099
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase 1 (PARP1) promotes oxidative stress-induced association of Cockayne syndrome group B protein with chromatin.
Boetefuer EL; Lake RJ; Dreval K; Fan HY
J Biol Chem; 2018 Nov; 293(46):17863-17874. PubMed ID: 30266807
[TBL] [Abstract][Full Text] [Related]
13. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
Li T; Xiong Y; Wang Q; Chen F; Zeng Y; Yu X; Wang Y; Zhou F; Zhou Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
[TBL] [Abstract][Full Text] [Related]
14. Targeting CDK4/6 in patients with cancer.
Hamilton E; Infante JR
Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286
[TBL] [Abstract][Full Text] [Related]
15. Transient OGG1, APE1, PARP1 and Polβ expression in an Alzheimer's disease mouse model.
Lillenes MS; Støen M; Gómez-Muñoz M; Torp R; Günther CC; Nilsson LN; Tønjum T
Mech Ageing Dev; 2013 Oct; 134(10):467-77. PubMed ID: 24121118
[TBL] [Abstract][Full Text] [Related]
16. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
17. Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer.
Sumi NJ; Kuenzi BM; Knezevic CE; Remsing Rix LL; Rix U
ACS Chem Biol; 2015 Dec; 10(12):2680-6. PubMed ID: 26390342
[TBL] [Abstract][Full Text] [Related]
18. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
[TBL] [Abstract][Full Text] [Related]
19. PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer.
Zhao B; Burgess K
Chem Commun (Camb); 2019 Feb; 55(18):2704-2707. PubMed ID: 30758029
[TBL] [Abstract][Full Text] [Related]
20. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
